-
Something wrong with this record ?
Outcomes of ventricular tachycardia ablation in patients with structural heart disease: The impact of electrical storm
B. Aldhoon, D. Wichterle, P. Peichl, R. Čihák, J. Kautzner,
Language English Country United States
Document type Journal Article
NLK
Directory of Open Access Journals
from 2006
Free Medical Journals
from 2006
Public Library of Science (PLoS)
from 2006
PubMed Central
from 2006
Europe PubMed Central
from 2006
ProQuest Central
from 2006-12-01
Open Access Digital Library
from 2006-10-01
Open Access Digital Library
from 2006-01-01
Open Access Digital Library
from 2006-01-01
Medline Complete (EBSCOhost)
from 2008-01-01
Nursing & Allied Health Database (ProQuest)
from 2006-12-01
Health & Medicine (ProQuest)
from 2006-12-01
Public Health Database (ProQuest)
from 2006-12-01
ROAD: Directory of Open Access Scholarly Resources
from 2006
- MeSH
- Ventricular Fibrillation complications MeSH
- Catheter Ablation adverse effects MeSH
- Tachycardia, Ventricular complications pathology surgery MeSH
- Middle Aged MeSH
- Humans MeSH
- Postoperative Complications epidemiology MeSH
- Aged MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
AIMS: To investigate predictors of long-term outcomes after catheter ablation (CA) for ventricular tachycardia (VT) and the impact of electrical storm (ES) prior to index ablation procedures. METHODS: We studied consecutive patients with structural heart disease and VT (n = 328; age: 63±12 years; 88% males; 72% ischaemic cardiomyopathy; LVEF: 32±12%) who had undergone CA. According to presenting arrhythmia at baseline, they were divided into ES (n = 93, 28%) and non-ES groups. Clinical predictors of all-cause mortality were investigated and a clinically useful risk score (SCORE) was constructed. RESULTS: During a median follow-up of 927 days (IQR: 564-1626), 67% vs. 60% of patients (p = 0.05) experienced VT recurrence in the ES vs. the non-ES group, respectively; and 41% vs. 32% patients died (p = 0.02), respectively. Five factors were independently associated with mortality: age >70 years (hazard ratio (HR): 1.6, 95% confidence interval (CI): 1.1-2.4, p = 0.01), NYHA class ≥3 (HR: 1.9, 95% CI: 1.2-2.9, p = 0.005), a serum creatinine level >1.3 mg/dL (HR: 1.6, 95% CI: 1.1-2.3, p = 0.02), LVEF ≤25% (HR: 2.4, 95% CI: 1.6-3.5, p = 0.00004), and amiodarone therapy (HR: 1.5, 95% CI: 1.0-2.2, p = 0.03). A risk SCORE ranging from 0-4 (1 point for either high-risk age, NYHA, creatinine, or LVEF) correlated with mortality. ES during index ablation independently predicted mortality only in patients with a SCORE ≤1. CONCLUSIONS: Advanced LV dysfunction, older age, higher NYHA class, renal dysfunction, and amiodarone therapy, but not ES, were predictors of poor outcomes after CA for VT in the total population. However, ES did predict mortality in a low-risk sub-group of patients.
Department of Cardiology Institute for Clinical and Experimental Medicine IKEM Prague Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17031054
- 003
- CZ-PrNML
- 005
- 20181022105357.0
- 007
- ta
- 008
- 171025s2017 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1371/journal.pone.0171830 $2 doi
- 035 __
- $a (PubMed)28187168
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Aldhoon, Bashar $u Department of Cardiology, Institute for Clinical and Experimental Medicine - IKEM, Prague, Czech Republic. $7 gn_A_00003665
- 245 10
- $a Outcomes of ventricular tachycardia ablation in patients with structural heart disease: The impact of electrical storm / $c B. Aldhoon, D. Wichterle, P. Peichl, R. Čihák, J. Kautzner,
- 520 9_
- $a AIMS: To investigate predictors of long-term outcomes after catheter ablation (CA) for ventricular tachycardia (VT) and the impact of electrical storm (ES) prior to index ablation procedures. METHODS: We studied consecutive patients with structural heart disease and VT (n = 328; age: 63±12 years; 88% males; 72% ischaemic cardiomyopathy; LVEF: 32±12%) who had undergone CA. According to presenting arrhythmia at baseline, they were divided into ES (n = 93, 28%) and non-ES groups. Clinical predictors of all-cause mortality were investigated and a clinically useful risk score (SCORE) was constructed. RESULTS: During a median follow-up of 927 days (IQR: 564-1626), 67% vs. 60% of patients (p = 0.05) experienced VT recurrence in the ES vs. the non-ES group, respectively; and 41% vs. 32% patients died (p = 0.02), respectively. Five factors were independently associated with mortality: age >70 years (hazard ratio (HR): 1.6, 95% confidence interval (CI): 1.1-2.4, p = 0.01), NYHA class ≥3 (HR: 1.9, 95% CI: 1.2-2.9, p = 0.005), a serum creatinine level >1.3 mg/dL (HR: 1.6, 95% CI: 1.1-2.3, p = 0.02), LVEF ≤25% (HR: 2.4, 95% CI: 1.6-3.5, p = 0.00004), and amiodarone therapy (HR: 1.5, 95% CI: 1.0-2.2, p = 0.03). A risk SCORE ranging from 0-4 (1 point for either high-risk age, NYHA, creatinine, or LVEF) correlated with mortality. ES during index ablation independently predicted mortality only in patients with a SCORE ≤1. CONCLUSIONS: Advanced LV dysfunction, older age, higher NYHA class, renal dysfunction, and amiodarone therapy, but not ES, were predictors of poor outcomes after CA for VT in the total population. However, ES did predict mortality in a low-risk sub-group of patients.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a katetrizační ablace $x škodlivé účinky $7 D017115
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a pooperační komplikace $x epidemiologie $7 D011183
- 650 _2
- $a komorová tachykardie $x komplikace $x patologie $x chirurgie $7 D017180
- 650 _2
- $a fibrilace komor $x komplikace $7 D014693
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Wichterle, Dan $u Department of Cardiology, Institute for Clinical and Experimental Medicine - IKEM, Prague, Czech Republic.
- 700 1_
- $a Peichl, Petr, $u Department of Cardiology, Institute for Clinical and Experimental Medicine - IKEM, Prague, Czech Republic. $d 1976- $7 xx0092197
- 700 1_
- $a Čihák, Robert $u Department of Cardiology, Institute for Clinical and Experimental Medicine - IKEM, Prague, Czech Republic.
- 700 1_
- $a Kautzner, Josef $u Department of Cardiology, Institute for Clinical and Experimental Medicine - IKEM, Prague, Czech Republic.
- 773 0_
- $w MED00180950 $t PloS one $x 1932-6203 $g Roč. 12, č. 2 (2017), s. e0171830
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28187168 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20171025 $b ABA008
- 991 __
- $a 20181022105902 $b ABA008
- 999 __
- $a ok $b bmc $g 1254647 $s 992081
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 12 $c 2 $d e0171830 $e 20170210 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
- LZP __
- $a Pubmed-20171025